By watching brain organoids develop, researchers observed surprising abnormalities caused by mutations in a gene related to early-onset Alzheimer’s disease.
Slight modifications to glycoproteins reveal critical insights into disease onset, state, and progression, making them a wellspring for biomarker discovery.
A small molecule called ALGERNON2 improved health outcomes in mouse models of neurodegenerative diseases by activating antioxidant pathways in astrocytes.
A new form of brain stimulation treatment that responds to a patient’s brain activity could be life changing for people with neurological and psychiatric disorders.
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.